Propafenone-related cholestatic hepatitis in an elderly patient

Italian Heart Journal

Volumn 3, Issue 7, 2002, Pages 431-434

  Grieco, Antonio ^a   Forgione, Alessandra ^a   Giorgi, Andrea ^a   Miele, Luca ^a   Gasbarrini, Giovanni ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Aging; Arrhythmias; Drugs; Hepatic disease; Propafenone; Side effects; Supraventricular

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INFUSION FLUID; PROPAFENONE; URSODEOXYCHOLIC ACID;

AGED; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG METABOLISM; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; LIVER METABOLISM; MALE; SYMPTOMATOLOGY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; CHOLESTASIS, INTRAHEPATIC; HEPATITIS, TOXIC; HUMANS; MALE; PROPAFENONE; TREATMENT OUTCOME;

EID: 0036657714     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bryson HM, Palmer KJ, Langtry HD, Fitton A. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias. Drugs 1993; 45: 85-130.
2. Reimold SC. Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Eur Heart J 1997; 18 (Suppl C): C40-C44.
3. Schlepper M. Propafenone, a review of its profile. Eur Heart J 1987; 8 (Suppl A): 27-32.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994.
5. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
6. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.
7. Zimmerman HJ, Ishak GK. General aspects of drug induced liver disease. Gastroenterol Clin North Am 1995; 24: 739-54.
8. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on adverse drug reaction between 1978 and 1987. J Intern Med 1992; 232: 133-8.
9. Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275-311.
10. Grieco A, Greco AV, Vecchio FM, Gasbarrini G. Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 1998; 10: 713-5.
11. Gasbarrini G, Grieco A, Miele L, et al. Drug-induced liver disease. Ann Ital Med Int 2001; 16 (Suppl 4): 1S-80S.
12. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-27.
13. Zimmerman HJ. Hepatotoxicity. The adverse effect of drugs and other chemicals on the liver. Philadelphia, PA: Lippincott & Wilkins, 1999.
14. Davidson CS, Leevy CM, Chamberlayne EC. Guidelines for detection of hepatotoxicity due to drugs and chemicals. NIH Publication no. 79-313. Washington, DC Department of Health, Education, and Welfare, 1979.
15. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24: 483-90.
16. Lee JT, Yee YG, Dorian P, Kates RE. Influence of hepatic dysfunction on the pharmacokinetics of propafenone. J Clin Pharmacol 1987; 27: 384-9.
17. Meyer UA. Pharmacogenetics - the slow, the rapid and the ultrarapid. Proc Natl Acad Sci USA 1994; 91: 1983-4.
18. Hii J, Duff HJ, Burgess ED. Clinical pharmacology of propafenone. Clin Pharmacokinet 1991; 21: 1-10.
19. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46: 377-94.
20. Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med 1990; 322: 518-25.